Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$3.34 - $4.29 $38,744 - $49,764
11,600 New
11,600 $42,000
Q1 2022

May 16, 2022

SELL
$2.62 - $4.45 $110,461 - $187,616
-42,161 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$4.05 - $5.37 $170,752 - $226,404
42,161 New
42,161 $184,000

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.81B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.